Donald Healey, Ph.D., has served as Adicet Bio's Chief Technology Officer since October 2020. From February 2017 to October 2020 he was Senior Vice President, Operations and Site Head for KBI Biopharma, a biopharmaceutical contract services organization.
From April 2010 to February 2017 he held multiple roles including Chief Scientific Officer at Opexa Therapeutics, responsible for preclinical scientific development, closed-system process design and the scaling of Opexa's autologous T-cell immunotherapy, and earlier held positions at Argos Therapeutics and ML Laboratories. He received his Ph.D. in Cellular Immunology from the University of London and holds a B.Sc. in Cellular Pathology from Bristol University.